Prudent cost management in H1; FY20 goals reinstated
01/08/20 -"As expected, the consumer healthcare segment and the neurosciences franchisee were adversely impacted by the pandemic, though the oncology franchisee provided the much needed resilience. ..."
Pages
50
Language
English
Published on
01/08/20
You may also be interested by these reports :
20/02/26
After incorporating the 2025 financials, we have added a new forecast year to our model, which expects a continuation of growth at Novartis. The firm ...
20/02/26
Expanding margins despite moderate topline growth
18/02/26
After Bayer announced that it will settle most of the Roundup (glyphosate; herbicide) related class action suits (alleging Non-Hodgkin’s lymphoma, a ...
18/02/26
Genmab’s full-year 2025 results showed both sales and adjusted operating profit falling short of market expectations. Despite this, double-digit ...